Santosh Taur, Namrata Kulkarni, Sachin Choudhari, Ahuva Averin, Anu Suokas, Mary MacKinnon, Mark Atwood, Liping Huang
{"title":"Simplifying Adult Pneumococcal Vaccination in India: A Cost-Effectiveness Analysis of the 20-Valent Conjugate Vaccine.","authors":"Santosh Taur, Namrata Kulkarni, Sachin Choudhari, Ahuva Averin, Anu Suokas, Mary MacKinnon, Mark Atwood, Liping Huang","doi":"10.1007/s40121-026-01464-8","DOIUrl":null,"url":null,"abstract":"<p><strong>Introduction: </strong>In India, adult pneumococcal disease prevention relies on the 23‑valent pneumococcal polysaccharide vaccine (PPSV23) and the 13‑ and 20‑valent pneumococcal conjugate vaccines (PCV13, PCV20). Before PCV20 introduction, adults at older age or high risk typically received PCV13 followed by PPSV23, although no national recommendation exists and uptake has been low. This study evaluated the cost‑effectiveness of a single‑dose PCV20 strategy compared with the sequential PCV13→PPSV23 regimen from private and public perspectives.</p><p><strong>Methods: </strong>Incremental cost‑effectiveness ratios (ICERs) per quality‑adjusted life‑year (QALY) gained were estimated for PCV20 versus PCV13→PPSV23. Analyses were conducted from the private perspective for high‑risk adults aged 18-49 years and all adults aged ≥ 50 years, and from the government perspective for high‑risk adults aged 18-59 years and all adults aged ≥ 60 years.</p><p><strong>Results: </strong>Compared with PCV13→PPSV23, PCV20 was projected to reduce pneumococcal disease cases and deaths and was cost‑effective under the 3× GDP per capita threshold. PCV20 generated 18,186 and 44,659 additional QALYs from the private and public perspectives, with incremental costs of ₹2.0 billion (Indian Rupees; medical: -₹17.4B; vaccine: ₹19.4B) and ₹25.5B (medical: -₹3.6B; vaccine: ₹29.1B), yielding ICERs of ₹110,790 and ₹570,327 per QALY, respectively. PCV20 was cost‑effective in 92.4% and 75.0% of probabilistic simulations from the private and government perspectives. Extending vaccination to at‑risk adults aged 18-49 years remained cost‑effective from the private perspective (ICER: ₹292,531/QALY).</p><p><strong>Conclusions: </strong>A single‑dose PCV20 strategy for high‑risk and older adults in India is cost‑effective compared with the current sequential regimen and may simplify pneumococcal vaccination and potentially improve uptake.</p>","PeriodicalId":13592,"journal":{"name":"Infectious Diseases and Therapy","volume":" ","pages":""},"PeriodicalIF":5.6000,"publicationDate":"2026-10-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Infectious Diseases and Therapy","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1007/s40121-026-01464-8","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"INFECTIOUS DISEASES","Score":null,"Total":0}
引用次数: 0
Abstract
Introduction: In India, adult pneumococcal disease prevention relies on the 23‑valent pneumococcal polysaccharide vaccine (PPSV23) and the 13‑ and 20‑valent pneumococcal conjugate vaccines (PCV13, PCV20). Before PCV20 introduction, adults at older age or high risk typically received PCV13 followed by PPSV23, although no national recommendation exists and uptake has been low. This study evaluated the cost‑effectiveness of a single‑dose PCV20 strategy compared with the sequential PCV13→PPSV23 regimen from private and public perspectives.
Methods: Incremental cost‑effectiveness ratios (ICERs) per quality‑adjusted life‑year (QALY) gained were estimated for PCV20 versus PCV13→PPSV23. Analyses were conducted from the private perspective for high‑risk adults aged 18-49 years and all adults aged ≥ 50 years, and from the government perspective for high‑risk adults aged 18-59 years and all adults aged ≥ 60 years.
Results: Compared with PCV13→PPSV23, PCV20 was projected to reduce pneumococcal disease cases and deaths and was cost‑effective under the 3× GDP per capita threshold. PCV20 generated 18,186 and 44,659 additional QALYs from the private and public perspectives, with incremental costs of ₹2.0 billion (Indian Rupees; medical: -₹17.4B; vaccine: ₹19.4B) and ₹25.5B (medical: -₹3.6B; vaccine: ₹29.1B), yielding ICERs of ₹110,790 and ₹570,327 per QALY, respectively. PCV20 was cost‑effective in 92.4% and 75.0% of probabilistic simulations from the private and government perspectives. Extending vaccination to at‑risk adults aged 18-49 years remained cost‑effective from the private perspective (ICER: ₹292,531/QALY).
Conclusions: A single‑dose PCV20 strategy for high‑risk and older adults in India is cost‑effective compared with the current sequential regimen and may simplify pneumococcal vaccination and potentially improve uptake.
期刊介绍：
Infectious Diseases and Therapy is an international, open access, peer-reviewed, rapid publication journal dedicated to the publication of high-quality clinical (all phases), observational, real-world, and health outcomes research around the discovery, development, and use of infectious disease therapies and interventions, including vaccines and devices. Studies relating to diagnostic products and diagnosis, pharmacoeconomics, public health, epidemiology, quality of life, and patient care, management, and education are also encouraged.
Areas of focus include, but are not limited to, bacterial and fungal infections, viral infections (including HIV/AIDS and hepatitis), parasitological diseases, tuberculosis and other mycobacterial diseases, vaccinations and other interventions, and drug-resistance, chronic infections, epidemiology and tropical, emergent, pediatric, dermal and sexually-transmitted diseases.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
